64395-31-9

Usage

Abbreviation

2-AI

Type

Synthetic organic compound

Structure

Purine derivative, structurally related to adenine

Biological Activity

Acts as a selective agonist at the adenosine A2A receptor

Receptor Type

G-protein coupled receptor (adenosine A2A receptor)

Distribution

Widely distributed in the central nervous system

Potential Applications

Treatment of neurodegenerative diseases such as Parkinson's and Alzheimer's
Management of symptoms associated with neurodegenerative diseases
Potential use as a stimulant
Potential treatment for attention deficit hyperactivity disorder (ADHD)

InChI:InChI=1/C10H13N5O3/c11-9-7-10(13-3-12-9)15(4-14-7)5-2-18-6(1-16)8(5)17/h3-6,8,16-17H,1-2H2,(H2,11,12,13)

Upstream product

• 265137-12-0 2'-deoxycytidylyl(5'->3')-1'-deoxy-2'-isoadenosine 

Relevant academic research and scientific papers

Resistance towards exonucleases of dinucleotides with stereochemically altered internucleotide phosphate bonds

Kinetic constants for the hydrolytic susceptibility of the internucleotide phosphate bond in normal dinucleotides [e.g., 2′-deoxycytidylyl- (3′>5′)-2′-deoxyuridine (dCpdU) and 2′-deoxyadenylyl- (3′→5′)-2′-deoxycytidine (dApdC)] and isomeric dinucleotides

Recognition and inhibition of HIV integrase by novel dinucleotides

HIV integrase is involved in the integration of viral DNA into chromosomal DNA, a biological process that occurs by a sequence involving HIV DNA splicing and subsequent integration steps. In the quest for small nucleotide systems with nuclease stability of the internucleotide phosphate bond and critical structural features for recognition and inhibition of HIV-1 integrase, we have discovered novel, nuclease-resistant dinucleotides with defined base sequences that are inhibitors of this key viral enzyme. Synthetic methodologies utilized for the syntheses of the novel dinucleotides include an excellent new phosphorylating agent.